[ad_1]
Viatrice Statement Regarding Termination of Global Research and Development Partnership with Idorsia
Pittsburgh, March 18, 2024 – As previously disclosed on February 28, 2024, Viatris Inc. has entered into a global research and development collaboration agreement with Idorsia Ltd (SIX: IDIA). The transaction closed on March 15, 2024. For more information regarding the transaction, please refer to Viatris’ Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission.
Research and development events
Viatrice will hold a research and development event in New York City on March 27, 2024 from 10 a.m. to noon ET.
The event will include presentations from Viatris executives discussing the collaboration with Idorsia and other elements of our pipeline, as well as presentations from two expert thought leaders. Presenters can answer questions at the end of their presentation.
Expert thought leaders who will be speaking at the event include:
- Dr. Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, is a top expert in cardiovascular medicine and interventional cardiology and director of Mount Sinai Faster Heart Hospital. Dr. Bhatt is recognized for important advances in the fields of cardiology, including interventional cardiology, heart disease prevention, vascular medicine, and heart failure.
- Dr. Anka Askanadze is the founder and clinical director of Columbia University’s new Lupus Center and director of rheumatology clinical trials. Dr. Askanase is an internationally renowned clinician, diagnostician, and researcher who has specialized in complex SLE for over 15 years. Dr. Askanase trained as a rheumatologist at New York University, where he served as a faculty member for over 15 years, directed clinical trials, and trained fellows and residents, and at New York University’s prestigious hospital, where he studied the difficulties of SLE. I have treated several cases.
Interested parties can access a live webcast of the event at investor.viatris.com. An archived version will also be published after the live event and will be accessible for a limited time in the same location.
About Viatrice
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional gap between generic and branded medicines, combining the best of both worlds to more comprehensively address healthcare needs around the world. corresponds to With a mission to help people around the world live healthier lives at every stage of life, we provide access at scale and currently provide access to high-quality medicines to approximately 1 billion patients annually worldwide. It touches every moment of life from birth to death. Life, from acute symptoms to chronic diseases. Our extremely broad and diverse portfolio of medicines, a unique global supply chain designed to reach more people when and where they need it, and address some of the world’s most enduring health challenges. You need access to the scientific expertise to do so. About the deep meaning of Viatrice. The company is headquartered in the United States with global centers in Pittsburgh, Shanghai, and Hyderabad, India. Learn more at viatris.com and investor.viatris.com. Also, connect with us on LinkedIn, Instagram, YouTube, and more. X (Formerly Twitter).
For more information: Contact: MEDIA +1.724.514.1968 Communications@viatris.com Jennifer Mauer Jennifer.Mauer@viatris.com Matt Klein Matthew.Klein@viatris.com Investors Bill Szablewski +1.412.707.2866 InvestorRelations@viatris.com William.Szablewski @viatrice.com
[ad_2]
Source link